The content on this site is intended for healthcare professionals only
Typical course for receptor positive early breast cancer
Bisphosphonates for breast cancer patients
Oral bisphosphonate and breast cancer: prospective results from the Women's Health Initiative (WHI)
Exemestane vs tamoxifen followed by exemestane
Bevacizumab plus docetaxel compared with placebo plus docetaxel for locally recurrent or metastatic breast cancer
Bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer
Lapatinib alone or in combination with trastuzumab for HER2+ metastatic breast cancer
A novel strategy in treating endocrine resistance using combination therapy
Sorafenib in combination with paclitaxel for locally recurrent or metastatic breast cancer
Fulvestrant 250 mg vs 500 mg in postmenopausal women with oestrogen receptor-positive advanced breast cancer
Targeting intrinsically-resistant breast cancer stem cells with gamma-secretase inhibitors
Short term biological effects of the combination of letrozole and zoledronic acid on invasive breast cancer
Denosumab versus zoledronic acid for skeletal-related events in breast cancer patients with bone metastases
Use of bisphosphonates and risk of postmenopausal breast cancer
Translation of endocrine systemic treatment
Using biology of tumours to predict effective therapies
Optimal way to use herceptin with adjuvant therapy
Cancer and the bone micro-environment
Emerging approaches to clinical trial design
Evaluating strategies for endocrine therapy
How life style factors effect survival of breast cancer patients
Fulvestrant as treatment for advanced breast cancer
Sentinel lymph node biopsy
Applying new proteomic technologies to improve patient management
Causes and prevention of breast cancer
Early breast cancer trials
New paradigms in tumour immunotherapy
San Antonio Breast Cancer Symposium, 9th-13th December 2009
